Literature DB >> 26596920

Medical Therapy for Inflammatory Bowel Disease.

Panayiotis Grevenitis1, Arul Thomas1, Nilesh Lodhia2.   

Abstract

Surgeons often care for patients with inflammatory bowel disease (IBD) who are receiving therapies that can include 5-ASA compounds, steroids, immunomodulators, and biologics. The goal of these agents is to suppress intestinal inflammation, ultimately improving the quality of life in patients afflicted with IBD. Traditionally, an acceptable therapeutic endpoint was the resolution of symptoms, defined as clinical remission. However, as a result of recent advances in therapy, clinicians can now strive to achieve more stringent endpoints, such as endoscopic or histologic remission. Many different classes of agents can be used, individually or in combination, to achieve mucosal healing.
Copyright © 2015 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Crohn's disease; Fistula; Fulminant colitis; Inflammatory bowel disease; Perioperative management; Ulcerative colitis

Mesh:

Substances:

Year:  2015        PMID: 26596920     DOI: 10.1016/j.suc.2015.08.004

Source DB:  PubMed          Journal:  Surg Clin North Am        ISSN: 0039-6109            Impact factor:   2.741


  10 in total

1.  Interleukin-25 enhances the capacity of mesenchymal stem cells to induce intestinal epithelial cell regeneration.

Authors:  Jingling Su; Chenxi Xie; Yanyun Fan; Weizi Cheng; Yiqun Hu; Qingwen Huang; Huaxiu Shi; Lin Wang; Jianlin Ren
Journal:  Am J Transl Res       Date:  2017-12-15       Impact factor: 4.060

2.  Effects of Immunomodulators and Biologic Agents on Sexual Health in Patients With Inflammatory Bowel Disease.

Authors:  Ozdemir Kanar; Andrew C Berry; Rahman Nakshabendi; Ann Joo Lee; Petra Aldridge; Travis Myers; Emely Eid
Journal:  Ochsner J       Date:  2017

3.  Distance to Specialist Care and Disease Outcomes in Inflammatory Bowel Disease.

Authors:  Nienke Z Borren; Grace Conway; William Tan; Elizabeth Andrews; John J Garber; Vijay Yajnik; Ashwin N Ananthakrishnan
Journal:  Inflamm Bowel Dis       Date:  2017-07       Impact factor: 5.325

4.  Squamous cell dysplasia in the proximal rectum of three patients treated for ulcerative colitis on immunomodulators.

Authors:  James G Connolly; Stephen E Goldstone
Journal:  Int J Colorectal Dis       Date:  2017-01-13       Impact factor: 2.571

5.  Cost-effectiveness analysis of fecal microbiota transplantation for inflammatory bowel disease.

Authors:  Ting Zhang; Jie Xiang; Bota Cui; Zhi He; Pan Li; Hai Chen; Lijuan Xu; Guozhong Ji; Yongzhan Nie; Kaichun Wu; Daiming Fan; Guangming Huang; Jianling Bai; Faming Zhang
Journal:  Oncotarget       Date:  2017-10-04

6.  A systems pharmacology model for inflammatory bowel disease.

Authors:  Violeta Balbas-Martinez; Leire Ruiz-Cerdá; Itziar Irurzun-Arana; Ignacio González-García; An Vermeulen; José David Gómez-Mantilla; Iñaki F Trocóniz
Journal:  PLoS One       Date:  2018-03-07       Impact factor: 3.240

7.  Effects of Boswellia Serrata Roxb. and Curcuma longa L. in an In Vitro Intestinal Inflammation Model Using Immune Cells and Caco-2.

Authors:  Paolo Governa; Maddalena Marchi; Veronica Cocetta; Bianca De Leo; Philippa T K Saunders; Daniela Catanzaro; Elisabetta Miraldi; Monica Montopoli; Marco Biagi
Journal:  Pharmaceuticals (Basel)       Date:  2018-11-20

Review 8.  Elucidating the Role of Innate and Adaptive Immune Responses in the Pathogenesis of Canine Chronic Inflammatory Enteropathy-A Search for Potential Biomarkers.

Authors:  Daniela Siel; Caroll J Beltrán; Eduard Martínez; Macarena Pino; Nazla Vargas; Alexandra Salinas; Oliver Pérez; Ismael Pereira; Galia Ramírez-Toloza
Journal:  Animals (Basel)       Date:  2022-06-27       Impact factor: 3.231

Review 9.  Strategies to improve the effect of mesenchymal stem cell therapy on inflammatory bowel disease.

Authors:  Meng-Yue Shi; Lian Liu; Fu-Yuan Yang
Journal:  World J Stem Cells       Date:  2022-09-26       Impact factor: 5.247

10.  Palmitoylethanolamide Modulates Inflammation-Associated Vascular Endothelial Growth Factor (VEGF) Signaling via the Akt/mTOR Pathway in a Selective Peroxisome Proliferator-Activated Receptor Alpha (PPAR-α)-Dependent Manner.

Authors:  Giovanni Sarnelli; Alessandra D'Alessandro; Teresa Iuvone; Elena Capoccia; Stefano Gigli; Marcella Pesce; Luisa Seguella; Nicola Nobile; Giovanni Aprea; Francesco Maione; Giovanni Domenico de Palma; Rosario Cuomo; Luca Steardo; Giuseppe Esposito
Journal:  PLoS One       Date:  2016-05-24       Impact factor: 3.240

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.